Brain detox promoter

Caffeoylquinic acid or its salts enhance brain detoxification by reducing lactic acid and increasing AQP4 expression, addressing the need for safe and continuous brain detoxification methods.

JP7595137B2Active Publication Date: 2024-12-05KAO CORP
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2023178840
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-10-17
Publication Date
2024-12-05
Estimated Expiration
2039-04-04

AI Technical Summary

Technical Problem

Existing technologies do not provide a safe and continuous method to promote brain detoxification, which is crucial for maintaining brain health and function, especially as aging and conditions like Alzheimer's disease impair waste excretion.

Method used

Caffeoylquinic acid or its salts are identified as safe ingredients that enhance the glymphatic system by reducing lactic acid levels in brain interstitial fluid and increasing AQP4 expression around cerebral blood vessels, promoting brain detoxification.

Benefits of technology

Caffeoylquinic acid or its salts effectively enhance brain detoxification by improving waste excretion, supporting brain health and function, particularly in conditions associated with impaired detoxification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595137000002
    Figure 0007595137000002
  • Figure 0007595137000003
    Figure 0007595137000003
  • Figure 0007595137000001
    Figure 0007595137000001
Patent Text Reader

Abstract

To provide a brain detox promoter that has high safety and can be continuously administered.SOLUTION: A brain detox promoter has caffeoylquinic acid or a salt thereof as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a brain detox promoter that expels waste products from the brain. [Background technology]

[0002] Brain and nervous system cells consume 20-25% of the total energy consumed by the body, and in the process A large amount of metabolites, namely water-soluble substances such as proteins and lactic acid, and lipophilic substances such as lipids, are produced in the It is excreted as a waste product (Non-Patent Document 1, Non-Patent Document 2). Waste removal from the periphery is carried out via the lymphatic system, but the brain does not have a lymphatic system. For this reason, it was previously thought that waste products were removed by brain cells on their own. However, in recent years, the Glymphatic system A waste removal system in the brain called the basal ganglion system was discovered (Non-Patent Documents 1 and 2). Cerebrospinal fluid (CSF) flows through the periarterial space, which is a cavity that surrounds the arteries. The outer wall is made up of astrocyte foot processes, and CSF is expressed in the astrocyte foot processes. Aquaporin 4 (AQP4), a water channel that functions as a membrane stimulator, transports water through arteries. From the periplasmic space, CSF flows into the astrocyte. Then, CSF seeps out of the astrocyte, It moves through the brain by convection, collects waste products, enters the perivenous space, and is excreted outside the brain. The transport of CSF by this waste removal system is mediated by AQP. The level of oxidative stress was significantly decreased in mice lacking 4 (Non-Patent Document 3), and mice with accumulated waste products It has been reported that AQP4 expression surrounding the perivascular space is decreased in patients with glaucoma (Non-Patent Document 4). do.

[0003] In addition, the brain's waste disposal is activated during sleep, and the amount of waste produced in the brain is greater during sleep than during wakefulness. For example, it has been found that the markers of neural activity are Lactic acid in brain tissue is used for the treatment of inflammatory bowel disease (Non-Patent Document 5). After it is produced in the tissue, the excess It has been reported that it is excreted through the brain's waste excretion system (Non-Patent Document 6), particularly during sleep. It has been reported that the amount of urine discharged during sleep increases compared to when the patient is awake and varies circadianly (Non-Patent Literature 7).

[0004] The excretion of such waste products is important for maintaining brain homeostasis and keeping its functions healthy. It is believed that such excretory functions decline with age. In mice with Marr's disease, waste excretion is reduced during sleep, resulting in unnecessary waste being stored in the brain. It has been reported that waste products accumulate in the brain (Non-Patent Documents 4 and 6). Materials that improve and promote brain detoxification, i.e. brain detox promoters, are effective in improving the decline in brain function that occurs with aging. It is useful for

[0005] On the other hand, chlorogenic acids, such as caffeoylquinic acid, are found in coffee beans. It has been found that it has an effect of suppressing blood sugar rise (Patent Document 1), enhancing sensory stimulation (Patent Document 2), and It has been reported that the improvement of blood fluidity leads to the excretion of waste products in the periphery (Patent Document 3). In addition, di-O-caffeoylquinic acid, which is an ester bond of two caffeic acids, binds to nerve cells. It has been reported to have a protective effect (Patent Document 4).

[0006] However, it is not known that caffeoylquinic acid has a detoxifying effect on the brain. . [Prior art documents] [Patent documents]

[0007] [Patent Document 1] JP 2003-34636 A [Patent Document 2] JP 2006-104071 A [Patent Document 3] JP 2004-168749 A [Patent Document 4] International Publication No. 2007 / 091613 [Non-patent literature]

[0008] [Non-Patent Document 1] Nedergaard M et al. Nikkei Science 2016.7:72-77. [Non-Patent Document 2] Jessen NA et al. Neurochem Res.2015.40:2583-2599. [Non-Patent Document 3] Iliff JJ et al. Sci Transl Med.2012.4:147ra111. [Non-Patent Document 4] Xu Z et al. Mol Neurodegener.2015.10:58. [Non-Patent Document 5] Uehara T et al. Pharmacol Biochem Behav.2008.90:273-281 [Non-Patent Document 6] Roh JH et al. Sci Transl Med.2012.4:150ra122. [Non-Patent Document 7] Lundgaard I et al. J Cereb Blood Flow Metab.2017.37:2112-2124. Summary of the Invention [Problem to be solved by the invention]

[0009] The present invention relates to providing a brain detox promoter that is highly safe and can be taken continuously. do. [Means for solving the problem]

[0010] The present inventors have been searching for various highly safe ingredients that can be taken or ingested for a long period of time. As a result of further investigation, it was found that caffeoylquinic acid reduced the amount of lactate in the interstitial fluid around the hippocampus during sleep, In addition, it increases the expression of AQP4 around the cerebral blood vessels in the hippocampus, which may contribute to the activation of the glymphatic system. We found that this is useful for promoting brain function, i.e., brain detoxification.

[0011] That is, the present invention relates to the following 1) to 6). 1) A brain detox promoter containing caffeoylquinic acid or its salt as an active ingredient. 2) Food for promoting brain detoxification, containing caffeoylquinic acid or its salt as an active ingredient. 3) A glymphatic system promoter containing caffeoylquinic acid or its salt as an active ingredient . 4) For promoting the glymphatic system, containing caffeoylquinic acid or its salt as the active ingredient food. 5) An AQP4 expression promoter having caffeoylquinic acid or its salt as an active ingredient. 6) Food for promoting AQP4 expression, containing caffeoylquinic acid or its salt as an active ingredient. Effect of the Invention

[0012] According to the present invention, a medicine, food, or the like that promotes brain detoxification and is useful for maintaining or improving brain function is provided. Goods are provided. [Brief description of the drawings]

[0013] [Figure 1] FIG. 13 is a graph showing changes in lactate levels in interstitial fluid near the hippocampus due to caffeoylquinic acid. [Diagram 2] FIG. 13 is a graph showing changes in AQP4 expression levels around cerebral blood vessels in the hippocampus due to caffeoylquinic acid. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The "caffeoylquinic acid" of the present invention is 3 -Caffeoylquinic acid (3-CQA), 4-Caffeoylquinic acid (4-CQA) and 5-Caffeoylquinic acid (5-CQA) A general term for 5-CQA, and one or more of these can be used. However, it is preferred that it contains at least 5-caffeoylquinic acid.

[0015] The salt of the caffeoylquinic acid of the present invention may be a pharma- ceutically acceptable salt, such as a sodium salt. Alkaline metal salts such as potassium, alkaline earth metal salts such as magnesium and calcium, Organic amine salts such as monoethanolamine, diethanolamine, and triethanolamine, Examples include salts of basic amino acids such as arginine, lysine, histidine, and ornithine.

[0016] The caffeoylquinic acid or a salt thereof of the present invention may be used in the form of an extract of a plant containing the caffeoylquinic acid or a salt thereof, or a concentrate thereof. Although it can be obtained from the purified products thereof, isolated caffeoylquinic acid or its salts In addition, extracts, concentrates or other products of the plant that contain a large amount of caffeoylquinic acid or its salts The purified products thereof can also be used. The purification method and conditions are not particularly limited, and known methods and conditions can be used. Among these, extraction with an aqueous solution of ascorbic acid, an aqueous solution of citric acid, or hot water is preferred.

[0017] Examples of plant extracts containing caffeoylquinic acid or its salts include sunflower seeds, Unripe citron fruit, coffee beans, simmon leaves, pine cones, pine seed shells, oats Sweet potatoes, sugarcane, wheat, nanten leaves, burdock, carrots, cabbage, lettuce, almonds, etc. Choke, tomato, molokheiya, eggplant skin, pear, plum, peach, apricot, chili pepper Examples include those extracted from cherries, plum fruits, coltsfoot, and plants of the Vitaceae family. Among these, coffee bean extracts are preferred in terms of the caffeoylquinic acid content, and roasted coffee is preferred. Although whole beans may be used, lightly roasted coffee beans, slightly roasted coffee beans, and green coffee beans are preferred. The types of coffee trees include Arabica, Robusta, Liberica, and Arabusta. This is also fine.

[0018] When a coffee bean extract is used as the caffeoylquinic acid or a salt thereof of the present invention, Preferably, the caffeine is removed, and the mass ratio of caffeine to caffeoylquinic acid or a salt thereof is [Caffeine / caffeoylquinic acid or its salt (hereinafter, caffeoylquinic acid equivalent)] From the viewpoint of flavor, the value is preferably 0.1 or less, more preferably 0.06 or less, and most preferably 0.04 or less. It is more preferable that the lower limit of the ratio of caffeine to caffeoylquinic acid or a salt thereof is not particularly limited. may be 0. The coffee bean extract is a mixture of potassium (K) and sodium (Na) and caffeoyl caffeine. The mass ratio of caffeoylquinic acid or its salt [(K+Na) / caffeoylquinic acid or its salt] is the most important factor in determining flavor. Therefore, it is preferably 0.4 or less, more preferably 0.3 or less, even more preferably 0.2 or less, and even more preferably 0.1 or less. The lower limit of the mass ratio [(K+Na) / caffeoylquinic acid or a salt thereof] is not particularly limited, and is 0 However, from the viewpoint of production efficiency, it is preferably 0.0002, and more preferably 0.002.

[0019] As shown in Example 1 below, caffeoylquinic acid inhibits the activity of the hippocampus during sleep in mice. It has the effect of reducing the amount of lactate in the interstitial fluid. In the brain, lactate is released in response to neuronal activity. It is an energy substrate produced by astrocytes in response to stress and is essential for maintaining neuronal activity and function. This is very important for the functioning of the brain (Cell Metabo, 14:724-738, 2011). Acid is used as a marker of neural activity (Non-Patent Document 5), and is known to be a marker of brain (nerve) function. During wakefulness, the brain tissue concentration is high because of the need for energy substrates, and the brain interstitial fluid concentration increases. On the other hand, it has been reported that after being produced in brain tissue, It has been reported that the excess lactic acid is excreted by the brain's waste excretion system (see previous article). In particular, the amount of cerebral interstitial fluid discharge increases during sleep compared to when the patient is awake, and the concentration of cerebral interstitial fluid is low. It has been reported that there is a diurnal variation in the amount of cerebral interstitial fluid (Non-Patent Document 7). Measuring the amount of lactate in the brain and observing its daily fluctuations can help determine whether waste products are being excreted normally. In mice with reduced brain waste excretion function, milk in the brain interstitial fluid during sleep was also found to be an indicator of sleep. It has been reported that the amount of acidity is increased, resulting in the accumulation of unnecessary waste products in the brain. (Non-patent document 6).

[0020] As shown in Example 2 below, caffeoylquinic acid inhibits cerebral blood vessels in the hippocampus of mice. It acts to increase the amount of AQP4 expression in the surrounding area. AQP4 is a component of the outer wall of the perivascular space. It is expressed in the foot processes of astrocytes, which are involved in the waste removal system (glymphatic system). It is very important for the transport of CSF by the endothelial cell (the endothelial cell system) (Non-Patent Documents 1, 2, and 3 mentioned above). In the literature, it was reported that AQP4 expression surrounding blood vessels was decreased in mice with accumulated waste products. It has been reported that the expression of AQP4 around cerebral blood vessels indicates that waste products are being excreted normally from the brain. This is an indicator of whether the glymphatic system is functioning properly. do.

[0021] Therefore, it is thought that the effect of reducing the amount of lactate in the brain interstitial fluid during sleep and AQP4 expression around the brain blood vessels is Caffeoylquinic acid and its salts, which have the effect of increasing the amount of glucose in the brain, are effective as brain detox promoters and as anti-glycemic agents. Brain detox promoters, AQP4 expression promoters (hereinafter referred to as "brain detox promoters, etc.") It can promote brain detoxification and stimulate the glymphatic system. Therefore, it can be used to promote AQP4 expression and to produce brain detox promoters, etc. It can be used to create Here, "use" can be administration or ingestion to a human or non-human animal, and can be therapeutic. The term "non-therapeutic" does not include medical procedures. concepts that do not involve methods of surgery, therapy or diagnosis of humans, more specifically medical This does not include the method by which a person under the direction of a doctor or physician performs surgery, treatment, or diagnosis on a human being. It is a new concept.

[0022] In the present invention, "promotion of brain detoxification" refers to the detoxification of various metabolites and waste products (e.g. Promoting the excretion of substances (e.g., proteins, lipids, lactic acid, etc.) from the brain and suppressing their accumulation in the brain. means...

[0023] In addition, "promotion of the glymphatic system" means the excretion of waste products from the brain through the perivascular space. It promotes the glymphatic system, which is the mechanism that excretes waste products, and suppresses the accumulation of waste products in the brain. This means:

[0024] In addition, "promotion of AQP4 expression" refers to the induction of transcription of the AQP4 gene into AQP4 mRNA. or inducing or promoting translation of AQP4 mRNA into AQP4 protein. and preferably promotes expression around cerebral blood vessels. AQP4 is a member of the aquaporin (AQP) family that has extremely high water selectivity. It is believed to be the major AQP involved in water transport in the brain.

[0025] In addition, in the present invention, the term "brain function" refers particularly to higher brain functions, specifically language and behavior. It refers to the various functions carried out by the brain, such as perception, cognition, memory, attention, judgment, and emotion. In addition, "improvement" means improvement of a disease, symptom, or condition, prevention of deterioration of a disease, symptom, or condition, or refers to delaying, or reversing, preventing or slowing the progression of a disease or condition.

[0026] The brain detox promoter of the present invention is itself a pharmaceutical agent for promoting brain detoxification. It may be a quasi-drug, supplement or food, or the said drug, quasi-drug, or The food additive may be a material or preparation to be incorporated into food. These foods include those that promote brain detoxification, glymphatic system stimulation, or aquapo Foods that are based on the concept of promoting phosphorylation and that, where necessary, are labeled as such, and functional foods These foods include foods for the sick, foods for specified health uses, and supplements. As it is an approved food, it can be distinguished from ordinary food.

[0027] The dosage form of the above-mentioned medicines (including quasi-drugs) may be, for example, tablets, capsules, granules, etc. Oral administration via tablets, powders, syrups, etc., or parenteral administration via injections, suppositories, inhalants, etc. In addition, such various dosage forms of preparations can be used in combination with the caffeoylquinic acid or The salt may be used alone or in combination with other pharma- ceutically acceptable excipients, binders, fillers, disintegrants, surfactants, etc. Agents, lubricants, dispersants, buffers, preservatives, flavorings, flavorings, coating agents, carriers, diluents, The drug is prepared by appropriately combining 5-caffeoylquinic acid or its salts with other medicinal ingredients. Of these administration forms, oral administration is preferred.

[0028] The above-mentioned foods may take the form of soft drinks, tea drinks, coffee drinks, fruit juice drinks, and carbonated drinks. Various types of food, beverages, and nutritional foods such as jellies, wafers, biscuits, bread, noodles, and sausages In addition to food, it can also be administered in the same form as the oral preparations mentioned above (tablets, capsules, syrups, etc.). etc.) nutritional supplement compositions are included.

[0029] The various forms of food products can be prepared by using the caffeoylquinic acid or a salt thereof of the present invention alone or in combination with other foods. Ingredients, solvents, softeners, oils, emulsifiers, preservatives, acidulants, sweeteners, bittering agents, flavorings, stabilizers, Coloring agents, antioxidants, moisturizers, thickeners, active ingredients other than caffeoylquinic acid or its salts, etc. can be prepared by appropriately combining The caffeoylquinic acid or its salt of the present invention in the above-mentioned medicines (including quasi-drugs) and foods The content can be appropriately determined depending on the form of use. For example, solid foods or oral preparations such as tablets, granules, pills, powders, gummies, etc. In the case of caffeoylquinic acid, the amount is preferably 0.01% by mass or more, and more preferably 0.1% by mass or more. More preferably, the content is 1% by mass or more, and even more preferably, 90% by mass or less. Oral preparations that are liquids, syrups, suspensions, emulsions, elixirs, jellies, etc. In the case of liquids such as preparations, the amount is preferably 0.001% by mass or more in terms of the amount of caffeoylquinic acid, and 0 It is more preferably 0.003% by mass or more, and even more preferably 0.01% by mass or more. It is preferably less than 10% by mass, more preferably 1% by mass or less, and even more preferably 1% by mass or less. In addition, the content is preferably 0.001 to 90% by mass, more preferably 0.003 to 10% by mass, and further preferably 0.001 to 90% by mass. The content is preferably 0.01 to 1% by mass.

[0030] The dosage or intake amount of the above medicines (including quasi-drugs) and foods may be determined appropriately. Generally, the recommended daily intake for an adult (60 kg) is caffeoylquinic acid equivalent. or 30 mg or more, more preferably 100 mg or more, and preferably 1000 mg or more. In the present invention, such an amount is administered at one time or It is preferable to consume it.

[0031] The above preparations may be administered or taken according to any schedule, and the administration or intake period is not particularly limited. However, repeated or continuous administration or ingestion is preferable, and administration or ingestion for 7 or more consecutive days is recommended. It is more preferable to administer or ingest the compound for 28 or more consecutive days. stomach.

[0032] The subjects for administration or ingestion are those who wish to prevent or improve brain function decline, promote brain detoxification, or improve glial function. Any human or non-human animal that requires or desires enhanced immune system functioning. It is effective for, but not limited to, administration or ingestion in humans.

[0033] With respect to the above-described embodiment, the present invention discloses the following aspects. <1> A brain detox promoter containing caffeoylquinic acid or its salt as an active ingredient. <2> A food for promoting brain detoxification, containing caffeoylquinic acid or its salt as an active ingredient. <3> Glymphatic system promotion using caffeoylquinic acid or its salt as an active ingredient Agent. <4> Glymphatic system promotion using caffeoylquinic acid or its salt as an active ingredient food for <5> An AQP4 expression promoter containing caffeoylquinic acid or its salt as an active ingredient. <6> A food for promoting AQP4 expression, containing caffeoylquinic acid or its salt as an active ingredient.

[0034] <7> Use of caffeoylquinic acid or a salt thereof for producing a brain detox promoter. <8> Use of caffeoylquinic acid or its salt for producing food for promoting brain detoxification For. <9> A method for producing a glymphatic system promoter, comprising: Use of salt. <10> Caffeoylquinic acid for the production of foods for promoting the glymphatic system or the use of its salts. <11> Use of caffeoylquinic acid or a salt thereof for producing an AQP4 expression promoter . <12> The present invention relates to a method for producing a food for promoting AQP4 expression, comprising administering to said food use.

[0035] <13> Caffeoylquinic acid or a salt thereof for use in promoting brain detoxification. <14> Non-therapeutic use of caffeoylquinic acid or its salts to promote brain detoxification For. <15> Caffeoylquinic acid or its derivatives for use in promoting the glymphatic system Salt. <16> Caffeoylquinic acid or its salts for promoting the glymphatic system Non-therapeutic use of. <17> Caffeoylquinic acid or a salt thereof for use in promoting AQP4 expression. <18> Non-therapeutic use of caffeoylquinic acid or its salts to promote AQP4 expression For.

[0036] <19> Caffeoylquinic acid or a salt thereof is administered orally in an effective amount to a subject in need thereof. is a method of promoting brain detox by ingestion. <20> Caffeoylquinic acid or a salt thereof is administered orally in an effective amount to a subject in need thereof. is a method of stimulating the glymphatic system through intake. <21> Caffeoylquinic acid or a salt thereof is administered orally in an effective amount to a subject in need thereof. is a method of promoting aquaporin 4 expression through ingestion.

[0037] <22> <1> , <3> , <5> , <7> , <9> or <11> Agents, <2> , <4> , <6> , <8> , <10> or <12> The content of the active ingredient in the food is In the case of solid products or oral preparations such as tablets, granules, pills, powders, gummies, etc. The amount of phenylquinic acid is preferably 0.01% by mass or more, and more preferably 0.1% by mass or more. It is preferably 1% by mass or more, and more preferably 90% by mass or less. Orally administered preparations such as liquids, syrups, suspensions, emulsions, elixirs, jellies, etc. In this case, the amount is preferably 0.001% by mass or more in terms of the amount of caffeoylquinic acid, and more preferably 0.003% by mass or more in terms of the amount of caffeoylquinic acid. % or more, more preferably 0.01% by mass or more, and even more preferably less than 90% by mass. It is preferably 10% by mass or less, more preferably 1% by mass or less, and further preferably 1% by mass or less. is 0.001 to 90 mass%, more preferably 0.003 to 10 mass%, and further preferably 0 It is .01 to 1 mass%. <23> <13> ~ <21> The daily dose for an adult is caffeine The amount of ruquinic acid is preferably 30 mg or more, more preferably 100 mg or more, and , preferably 1000 mg or less, more preferably 300 mg or less. EXAMPLES

[0038] Example 1: Effect of caffeoylquinic acid (5-CQA) on promoting brain detoxification (1) Manufacturing example: Preparation of animal feed The composition of the test diet (powdered feed) used in this study is shown in Table 1. The normal diet consisted of 61.5% potato. The 5-CQA diet contains potato starch equivalent to the amount of 5-CQA in the formula. The other ingredients (cold soybean extract, cold ... The amounts of carbohydrates, cellulose, minerals, and vitamins were the same in both the normal and 5-CQA diets. Corn oil, lard, casein, cellulose, AIN76 mineral mix, AIN76 in diet The vitamin mixture and potato starch used were manufactured by Oriental Yeast Co., Ltd.

[0039] [Table 1]

[0040] (2) Animals and breeding methods APP / PS2 double transgenic mice, a model mouse for Alzheimer's disease To generate (APP / PS2WTg), human amyloid plaques were used in the B6;SJL background. The K670N and M671L mutations (Swedish mutations) of the endothelial precursor protein (APP) were detected throughout the body. APP-Tg mice (Taconic Biosciences) and C57B The N141 mutation of human presenin 2 (PS2) was detected in the L / 6J mouse background. We used PS2-Tg mice (Oriental Yeast) with APP-Tg genes in the whole body. Sperm collected from males (10 weeks or older) and eggs from female PS2-Tg mice (4 weeks or older) The mother cells were subjected to in vitro fertilization to generate APP / PS2WTg mice. Male APP / PS2WTg mice were used, and the experimental group was administered 0.8 mass of 5-CQA prepared in the manufacturing example. The control group was given a standard diet for 4 months (n=100 for each group). 4-5).

[0041] (3) Measurement of lactate levels in interstitial fluid near the hippocampus The test was performed 4 months after the intake of the test diet. Using a position fixation device, a microdrill was placed in the hippocampus (A: -3.1, L: +2.5, V: -1.3 mm). A guide cannula for ialysis (Eicom Co., Ltd.) was inserted. After surgery, recovery took more than 4 days. After the period, a microdialysis probe (PEP-4-3, semipermeable membrane 3 mm, Eicom) was used. (Inc.) and 0.15% bovine serum albumin (Sigma) was administered. a-Aldrich) was added to artificial cerebrospinal fluid (NaCl: 145 mM, KCl: 12. 7 mM, CaCl2: 1.2 mM, MgCl2: 1.0 mM) at 10 μl / min After 3 hours from the start of perfusion, the perfusion rate was changed to 1 μl / min, and the intrahippocampal The interstitial fluid was sampled from 20:00 to 1:00 upon awakening, and from 8:00 The sample taken at ~13:00 was taken during sleep. orimetric / Fluorometric Assay kit(Bio Vi sion) was used for the measurements.

[0042] (4) Statistical analysis The analysis results are shown as the mean (Ave.) ± standard error (SE). The mean values ​​were compared using unpaired Student's t-test, and the P value was A value of 0.05 or less was determined to be statistically significant.

[0043] (5) Results The lactate levels during wakefulness did not change between the control and 5-CQA groups. The 5-CQA group showed a significant decrease in brain detoxification during sleep compared to the control group. It was revealed that the cytoplasmic function of the IL-1 receptor was promoted (Figure 1).

[0044] Example 2: Effect of caffeoylquinic acid (5-CQA) on increasing AQP4 expression around cerebrovascular tissue (1) Measurement of AQP4 expression levels around brain blood vessels in the hippocampus The same animals as those in Example 1 were used. After 4 months of feeding the test diet, Under deep anesthesia, mice were placed in ice-cold PBS containing heparin (5 U / mL) and 4% paraformaldehyde. A total of 15 mL of aldehyde-phosphate buffer (PFA) was perfused at a rate of approximately 3 mL / min. After perfusion, the whole brain was removed and immersed in 4% PFA, then refrigerated and fixed. After preparing the paraffin block, the dorsal hippocampus region was sliced ​​at 3 μm Brain sections were deparaffinized and washed with alcohol, running water, and TB. The mixture was washed with S. It was then activated with Proteinase K and washed with TBS. Next, the sections were immersed in a solution of 1% hydrogen peroxide in methanol, and then washed with TBS. Blocking was performed with 1:500 anti-AQP4 antibody (Millipore) After the reaction, the cells were washed with TBS and incubated with a biotin-labeled secondary antibody. A secondary antibody reaction was performed. After the reaction, the plate was washed with TBS and the sensitivity was amplified by the ABC method. After washing with TBS, the sections were stained with DAB. After nuclear staining with hematoxylin, The specimens were washed with running water, dehydrated, cleared, and mounted to prepare slide samples. All-in-one observation The analysis was performed using a microscope (BZX-710, Keyence) and the accompanying analysis software (BZ-II A The stained area of ​​the hippocampus and the stained area around the blood vessels were calculated using the The ratio of AQP4 expression to the surrounding area was calculated. The average stained area of ​​six sections per individual was calculated. The individual values ​​were used.

[0045] (2) Statistical analysis The analysis results are shown as the mean (Ave.) ± standard error (SE). The mean values ​​were compared using unpaired Student's t-test, and the P value was A value of 0.05 or less was determined to be statistically significant.

[0046] (3) Results From the observation images (Figure 2), AQP4 expression around the cerebral blood vessels in the hippocampus was 5-fold higher than in the control group. A clear increase was observed in the CQA group, and the AQP4 expression rate was significantly increased. An increase was observed (Figure 2).

Claims

1. A glymphatic system promoter containing caffeoylquinic acid or its salt as an active ingredient.

2. Glymphatic system promoting food containing caffeoylquinic acid or its salt as an active ingredient

3. An aquaporin 4 expression promoter comprising caffeoylquinic acid or its salt as an active ingredient.

4. A food for promoting aquaporin 4 expression, comprising caffeoylquinic acid or its salt as an active ingredient.

Citation Information

Patent Citations

  • Lipid metabolism-improving agent

    JP2003034636A

  • Blood flow improving agent

    JP2004168749A

  • Sense stimulation-reinforcing agent

    JP2006104071A

  • Brain function ameliorating agents

    JP2018039797A

  • Brain function improver and food and drink for brain function improvement

    JP2018052913A